Results 171 to 180 of about 4,766 (189)

Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV

Annals of Pharmacotherapy, 2019
Michelle M Foisy, Christine A Hughes
exaly  

Effects of a protein‐rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: A randomized, three‐way crossover study

Journal of Clinical Pharmacology, 2014
Shunji Matsuki, Tomohiro Ishikawa, Miyuki Kimura   +2 more
exaly  

Dolutegravir/elvitegravir/raltegravir

Reactions Weekly, 2019
openaire   +1 more source

Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV

Expert Review of Anti-Infective Therapy, 2017
Arkaitz Imaz, Daniel Podzamczer
exaly  

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment

Annals of Pharmacotherapy, 2012
Linda M Spooner, Olga M Klibanov
exaly  

Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients

HIV Clinical Trials, 2014
Rima Kulkarni, Michael E Abram, Javier Szwarcberg   +2 more
exaly  

A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection

Journal of Pharmacy Practice, 2018
Ayse Elif Özdener
exaly  

ELVITEGRAVIR / COBICISTAT /

2015
openaire   +1 more source

Cobicistat/elvitegravir/emtricitabine/tenofovir

Reactions Weekly, 2016
openaire   +1 more source

Pharmacokinetics of cobicistat boosted‐elvitegravir administered in combination with rosuvastatin

Journal of Clinical Pharmacology, 2014
Adrian S Ray, Andrew Cheng, Brian P Kearney   +2 more
exaly